Skip to main content
PepStack
Blutwerte · Marker

Aldosteron

Aldosterone · Mineralocorticoid

Hormone — StressachseZeitabhängig
Einheit:
ng/dL
Abbreviation
Aldo

Aldosterone measures the concentration of this mineralocorticoid hormone in the blood, reflecting adrenal gland function and RAAS activity.

Reference Ranges

Reference
0.140.42ng/dL
0.14
0.42
LowNormalHigh
Reference
Unit · ng/dL

Levels can vary based on posture, time of day, and sodium intake.

Overview

Übersicht

Aldosterone, abbreviated as Aldo, is a mineralocorticoid hormone produced by the adrenal glands. It plays a crucial role in regulating sodium and potassium balance, as well as blood pressure, by promoting sodium retention and potassium excretion in the kidneys. Researchers have found that aldosterone is part of the renin-angiotensin-aldosterone system (RAAS), which is critical for maintaining fluid balance and blood pressure homeostasis. Clinically, aldosterone levels are significant in diagnosing and managing conditions such as primary aldosteronism, Addison's disease, heart failure, and chronic kidney disease. Elevated aldosterone levels can lead to hypertension and cardiovascular damage, while low levels may indicate adrenal insufficiency. For athletes and biohackers, aldosterone's role in fluid and electrolyte balance is crucial, particularly in endurance sports where dehydration and electrolyte imbalances can impair performance. However, its relevance to longevity is less clear, though maintaining optimal levels may support cardiovascular health. Researchers observed that aldosterone levels can be influenced by factors such as posture, time of day, and dietary sodium intake, which can confound test results. Therefore, standardized testing conditions are recommended to ensure accurate assessment.

Klinische Bedeutung

Elevated aldosterone levels may indicate hyperaldosteronism, contributing to hypertension and cardiovascular disease. Reduced levels suggest adrenal insufficiency, such as Addison's disease, leading to symptoms like fatigue and hypotension.

Dynamics

Trend Interpretation

Rising Values

Progressively rising aldosterone levels suggest worsening hyperaldosteronism or RAAS activation; re-test in 4 weeks if elevated.

Falling Values

Progressively falling levels may indicate improving adrenal function or response to treatment.

Re-test Interval

4 weeks if outside optimal range

Etiology

Causes — High & Low

Cause

Elevated Levels

  • Primary hyperaldosteronism
  • Chronic kidney disease
  • Congestive heart failure
  • Liver cirrhosis
  • Renal artery stenosis
Cause

Low Levels

  • Addison's disease
  • Hypopituitarism
  • Congenital adrenal hyperplasia
  • Severe illness or stress
  • Medications such as ACE inhibitors
Protocol

How to Optimize

Lever

Lifestyle

  • Regular physical activity
  • Stress management techniques
  • Adequate hydration
  • Monitoring blood pressure regularly
Lever

Nutrition

  • Balanced sodium intake
  • Potassium-rich foods
  • Adequate magnesium intake
  • Avoiding excessive alcohol consumption

Note:

Consult a healthcare provider before making significant lifestyle or dietary changes, especially if on medication.

Testing Guidelines

Fasting Not Required
🕐Time-Sensitive

Aldosterone levels peak in the morning; testing should be consistent in timing.

Testing Frequency

Annually for those with hypertension or adrenal disorders.

Interfering Factors

  • Recent sodium intake
  • Posture during testing
  • Medications affecting RAAS

Related Peptides & Hormones

Cortisol

Correlated with

hormone

Open Research Questions

Current research suggests that the optimal aldosterone reference ranges and targets in various populations, particularly in cardio-kidney diseases, remain debated, with confounding factors such as concurrent medications and comorbidities complicating interpretations. Emerging research directions include the evaluation of selective aldosterone synthase inhibitors and their long-term effects on cardiovascular and renal outcomes. However, clinical questions remain unanswered regarding the precise role of aldosterone modulation in non-diabetic chronic kidney disease and its implications for treatment strategies.

19 Research Publications

451

Total Citations

2

Human/RCT

3.6

Avg. Influence

2024

Latest

Sort
Filter
#01

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.

Meta-AnalysisInfluence12.0
172
This meta-analysis investigated the risk of hyperkalemia associated with sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients. Researchers found that these inhibitors significantly reduced the risk of serious hyperkalemia without increasing hypokalemia risk.
View on PubMed
#02

Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.

In VitroInfluence5.0
57
Researchers studied baxdrostat, an aldosterone synthase inhibitor, in healthy volunteers. They observed a dose-dependent reduction in plasma aldosterone levels with no significant impact on cortisol, indicating its potential for treating conditions associated with elevated aldosterone.
View on PubMed
#03

Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management.

ReviewInfluence1.0
56
Researchers explored the clinical significance of hyperkalemia associated with renin-angiotensin-aldosterone system inhibitors, noting it as a common adverse effect. The study emphasized the need for effective management strategies to mitigate hyperkalemia while allowing continued use of these beneficial medications.
View on PubMed
#04

Canine hypoadrenocorticism: pathogenesis, diagnosis, and treatment.

ReviewInfluence3.0
55
This study examined hypoadrenocorticism in dogs, a condition caused by decreased adrenal hormone production. Researchers found that definitive diagnosis requires testing aldosterone levels along with cortisol levels. The prognosis is generally good with appropriate hormone supplementation.
View on PubMed
#05

Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen.

ReviewInfluence1.0
21
Researchers examined the pharmacological effects of drospirenone, a progestin, in various contraceptive formulations. The study highlighted its anti-mineralocorticoid activity, which may positively influence cardiovascular health, though the clinical relevance remains unclear.
View on PubMed
#06

A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist.

ReviewInfluence1.0
21
This study reviewed finerenone, a new mineralocorticoid receptor antagonist, and its effects on cardiovascular and renal diseases. Researchers found that finerenone demonstrated superior mechanisms compared to traditional MRAs, showing promise in treating patients with type 2 diabetes and chronic kidney disease.
View on PubMed
#07

Posaconazole-Induced Pseudohyperaldosteronism.

Case Report
20
This case report described a woman experiencing pseudohyperaldosteronism after treatment with posaconazole. Researchers found low renin and aldosterone levels, suggesting that the drug may inhibit an enzyme leading to apparent mineralocorticoid excess.
View on PubMed
#08

Diagnosis of canine spontaneous hypoadrenocorticism.

ReviewInfluence5.0
19
This review focused on canine hypoadrenocorticism, characterized by reduced adrenal hormone production. Researchers observed that affected dogs often present vague symptoms before a crisis, emphasizing the need for accurate classification and understanding of clinical features.
View on PubMed
#09

Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases.

ReviewInfluence1.0
14
Researchers found that excess aldosterone negatively impacts heart and kidney function through various mechanisms. This study highlighted the potential of mineralocorticoid receptor antagonists to mitigate these effects, although further research is needed to clarify their clinical implications in cardio-kidney diseases.
View on PubMed
#10

Real-world outcomes of finerenone in primary aldosteronism.

Case Report
8
This real-world study assessed the effects of switching primary aldosteronism patients from eplerenone to finerenone. Researchers observed a decrease in patients achieving normal blood pressure and biochemical response, indicating the need for further evaluation of finerenone's effectiveness.
View on PubMed

Publication Trend

Research publications about Aldosteron over time

7total
1
'14
2
'22
1
'23
1
'24
2
'25

Track your bloodwork in PepStack

Log lab results, track trends and optimize your biomarkers over time.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer